The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1593
March 9, 2020
View Complete Issue         Table of Contents 2019 
Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
March 9, 2020 (Issue: 1593)
Lasmiditan (Reyvow – Lilly), an oral serotonin (5-HT1F) receptor agonist, and ubrogepant (Ubrelvy – Allergan), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, have been approved by the FDA for acute treatment of migraine...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine
Article code: 1593b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.